EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma - PubMed
3 hours ago
- #EZH2
- #Hepatoblastoma
- #Therapeutic Target
- EZH2 is identified as a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.
- The study protocol was approved by ethical committees in France, with informed consent obtained from all participants.
- Drs C.F. Grosset, M Hagedorn, and F.Z. Khoubai are co-inventors of a pending patent related to the study.
- The research received funding from multiple sources including La Région Nouvelle-Aquitaine, Institut National Du Cancer, and the European Union's Horizon 2020 program.
- References include significant studies on hepatoblastoma risk stratification, genetics, and chemotherapy approaches.